Amryt Pharma PLC Holdings in Company (3165I)
11 Agosto 2021 - 7:30AM
UK Regulatory
TIDMAMYT
RNS Number : 3165I
Amryt Pharma PLC
11 August 2021
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and
to the FCA in Microsoft Word f ormat if possi b l e) i
1a. Identity of the issuer or the underlying
issuer of existing shares to which voting Amryt Pharma PLC
rights are at- tached ii :
-----------------------------------------------------------------
1b. Please indicate if the issuer is a non-UK issuer (please mark with
an "X" if appropriate)
Non-UK issuer
------------------
2. Reason for the notification (please mark the appropriate box or boxes
with an "X")
An acquisition or disposal of voting rights
------------------
An acquisition or disposal of financial instruments
------------------
An event changing the breakdown of voting rights X
------------------
Other (please specify) iii :
------------------
3 . D etails of person s u b j ect to the no t i f i ca t i on ob l i
ga t i o n iv
Name EdgePoint Investment Group Inc.
-----------------------------------------------------------------
City and country of registered office Toronto, Canada
(if applicable)
-----------------------------------------------------------------
4 . F u ll name of share h o l der(s) (if d i ff erent from 3 .) v
Name
-----------------------------------------------------------------
City and country of registered office
(if applicable)
-----------------------------------------------------------------
5. Date on which the threshold was 06/08/2021
crossed or reached vi :
-----------------------------------------------------------------
6. Date on which issuer notified (DD/MM/YYYY): 10/08/2021
-----------------------------------------------------------------
7. Total positions of person(s) subject to the notification obligation
% of voting rights % of voting rights Total number
at- tached to through financial Total of both of voting rights
shares (to- tal in- struments in % (8.A + 8.B) of is- suer
of 8. A) (total of 8.B 1 vii
+ 8.B 2)
---------------------- --------------------- ---------------------- ------------------
Resulting situation
on the date on
which
threshold was
crossed or reached 0% 3.71% 3.71% 307,118,662
---------------------- --------------------- ---------------------- ------------------
Position of previous
notification (if
applicable) 0% 7.93% 7.93%
---------------------- --------------------- ---------------------- ------------------
8. Notified details of the resulting situation on the date on which the
threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of Number of voting rights ix % of voting rights
shares
ISIN code (if
possible)
---------------------------------------------------- -----------------------------------------------------------
Direct Indirect Direct Indirect
(Art 9 of Directive (Art 10 of Directive (Art 9 of Directive (Art 10 of Directive
2004/109/EC) 2004/109/EC) 2004/109/EC) (DTR5.1) 2004/109/EC)
(DTR5.1) (DTR5.2.1) (DTR5.2.1)
----------------------- --------------------------- -------------------------------- -------------------------
SUBTOTAL 8. A
---------------------------------------------------- -----------------------------------------------------------
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC
(DTR5.3.1.1 (a))
Number of voting
Type of Expiration Exercise/ Conversion rights that may be % of voting rights
financial date x Period xi acquired if the instrument
in- strument is
exercised/converted.
---------------------- ---------------------------- -------------------------------- -------------------------
ADSs
US03217L1061 N/A N/A 11,389,820 3.71%
---------------------- ---------------------------- -------------------------------- -------------------------
SUBTOTAL 8. B 1 11,389,820 3.71%
---------------------------- -------------------------------- -------------------------
B 2: Financial Instruments with similar economic effect according to Art.
13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of Expiration Exercise/ Physical or Number of
financial date x Conversion cash voting rights % of voting rights
instrument Pe- riod xi settlement
xii
----------------------- --------------------------- --------------- ---------------- -------------------------
SUBTOTAL 8.B.2
--------------- ---------------- -------------------------
9. Information in relation to the person subject to the notification
obligation (please mark the applicable box with an "X")
Person subject to the notification obligation is not controlled by
any natural person or legal entity and does not control any other
undertaking(s) holding directly or indirectly an interest in the (underlying)
issuer xiii
----------------------------
Full chain of controlled undertakings through which the voting rights
and/or the X
financial instruments are effectively held starting with the ultimate
controlling natural person or legal entity xiv (please add additional
rows as necessary)
----------------------------
% of voting rights % of voting rights Total of both if
if it equals through financial it equals or is higher
N a or is higher in- struments if than the notifiable
me xv than the notifiable it equals or is higher threshold
threshold than the
notifiable threshold
---------------------------- --------------------------- ------------------------------
EdgePoint Investment Group
Inc.
---------------------------- --------------------------- ------------------------------
EdgePoint Wealth Manage-
ment Inc.
---------------------------- --------------------------- ------------------------------
10. In case of proxy voting, please identify:
Name of the proxy holder N/A
-----------------------------------------------------------
The number and % of voting rights held N/A
-----------------------------------------------------------
The date until which the voting rights N/A
will be held
-----------------------------------------------------------
11 . A dd iti on al i nformati on xvi
Full chain of controlled undertakings:
EdgePoint Investment Group Inc. EdgePoint Wealth Management Inc.
Place of completion Toronto, Canada
Date of completion 10/08/2021
----------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
HOLBFLFFFVLLBBK
(END) Dow Jones Newswires
August 11, 2021 06:30 ET (10:30 GMT)
Amryt Pharma (LSE:AMYT)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Amryt Pharma (LSE:AMYT)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
Notícias em tempo-real sobre Amryt Pharma Plc da Bolsa de Valores de Londres bolsa de valores: 0 artigos recentes
Mais Notícias de Amryt Pharma Plc
